Accelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures

Reuters05-13

<a href="https://laohu8.com/S/AXDX">Accelerate Diagnostics</a> Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures

Accelerate Diagnostics Inc. recently announced that it faces delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice from Nasdaq, citing public interest concerns related to the bankruptcy, as well as the company's failure to meet the minimum bid price and market value requirements. The company's stock, which has consistently closed below the $1.00 per share threshold, will be suspended from trading on Nasdaq starting May 15, 2025, and is expected to transition to the over-the-counter market under the symbol "AXDXQ." However, there is no guarantee that the shares will begin or continue trading in the OTC market. Accelerate Diagnostics Inc. does not plan to appeal the delisting decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047314), on May 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2535292781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535292781","market":"us","top_or_hot":-1,"title":"Accelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AXDX\">Accelerate Diagnostics</a> Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Accelerate Diagnostics Inc. recently announced that it faces delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice from Nasdaq, citing public interest concerns related to the bankruptcy, as well as the company's failure to meet the minimum bid price and market value requirements. The company's stock, which has consistently closed below the $1.00 per share threshold, will be suspended from trading on Nasdaq starting May 15, 2025, and is expected to transition to the over-the-counter market under the symbol \"AXDXQ.\" However, there is no guarantee that the shares will begin or continue trading in the OTC market. Accelerate Diagnostics Inc. does not plan to appeal the delisting decision.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047314), on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Accelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAccelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 04:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AXDX\">Accelerate Diagnostics</a> Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Accelerate Diagnostics Inc. recently announced that it faces delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice from Nasdaq, citing public interest concerns related to the bankruptcy, as well as the company's failure to meet the minimum bid price and market value requirements. The company's stock, which has consistently closed below the $1.00 per share threshold, will be suspended from trading on Nasdaq starting May 15, 2025, and is expected to transition to the over-the-counter market under the symbol \"AXDXQ.\" However, there is no guarantee that the shares will begin or continue trading in the OTC market. Accelerate Diagnostics Inc. does not plan to appeal the delisting decision.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047314), on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL5bkpgX:1","article_id":"2535292781","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535292781","pubTimestamp":1747081029,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Accelerate Diagnostics Inc. recently announced that it faces delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice from Nasdaq, citing public interest concerns related to the bankruptcy, as well as the company's failure to meet the minimum bid price and market value requirements. The company's stock, which has consistently closed below the $1.00 per share threshold, will be suspended from trading on Nasdaq starting May 15, 2025, and is expected to transition to the over-the-counter market under the symbol \"AXDXQ.\" However, there is no guarantee that the shares will begin or continue trading in the OTC market. Accelerate Diagnostics Inc. does not plan to appeal the delisting decision.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","AXDX":"Accelerate Diagnostics","AXDXQ":"Accelerate Diagnostics, Inc."},"translate_title":"Accelerate Diagnostics Inc.因申请破产和合规失败而面临从纳斯达克退市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXDX":0.9,"AXDXQ":0.9},"content_text":"Accelerate Diagnostics Inc. Faces Delisting from Nasdaq Following Bankruptcy Filing and Compliance Failures\n    \n\n        Accelerate Diagnostics Inc. recently announced that it faces delisting from the Nasdaq Stock Market following its voluntary Chapter 11 bankruptcy filing on May 8, 2025. The company received a delisting notice from Nasdaq, citing public interest concerns related to the bankruptcy, as well as the company's failure to meet the minimum bid price and market value requirements. The company's stock, which has consistently closed below the $1.00 per share threshold, will be suspended from trading on Nasdaq starting May 15, 2025, and is expected to transition to the over-the-counter market under the symbol \"AXDXQ.\" However, there is no guarantee that the shares will begin or continue trading in the OTC market. Accelerate Diagnostics Inc. does not plan to appeal the delisting decision.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-047314), on May 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2535292781","isCrawlerRequest":true}